METTL3 and neoplasm: The results presented in Figure 7B–E demonstrate that METTL3 overexpression significantly bolstered tumour xenograft resistance to anlotinib‐induced responses, an effect that was negated by co‐transfection with PRKDC shRNA lentivirus.